Medications

Mylan, like other generic drugmakers, feels the pricing pain

Mylan's second-quarter profit and revenue surged, but not as much as Wall Street had expected and the company is taking a more conservative view going forward because of "ongoing challenges and the uncertain U.S. regulatory ...

Medications

FDA approves lower-cost alternative to biotech drug Humira

Federal regulators on Friday approved the first alternative version of the second-best selling drug in the world, Humira, the blockbuster injection used to treat rheumatoid arthritis and other inflammatory diseases.

Medications

Teva to lift bid for Mylan: report

Israeli pharmaceutical giant Teva plans to increase its bid for rival Mylan and could announce the move as soon as this week, according to a US media report Monday.

page 3 from 5